1. Applying New Data in Practice:

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Goal: How do the DAPT guidelines and the latest clinical trial data for ACS management fit into practice?

5. 2016 ACC/AHA DAPT Guidelines P2Y12 Inhibitor Selection

6. 2016 ACC/AHA DAPT Guidelines DAPT Duration

7. 2017 ESC Update on DAPT in CAD P2Y12 Inhibitor Selection and Timing

8. 2017 ESC Update on DAPT in CAD P2Y12 Inhibitor Selection and Timing (cont)

9. 2017 ESC Update on DAPT in CAD Methods to Minimize Bleeding With DAPT

10. More Potent P2Y12 Inhibitors Are Recommended but Are Underused…

11. ARTEMIS Study Design

12. ARTEMIS Clinicians Are Sensitive to Patient Costs

13. ARTEMIS Nonpersistence of P2Y12 Inhibitor

14. ARTEMIS MACE and As-Treated Analysis

15. ARTEMIS Conclusions

16. ARTEMIS: Clinical Implications

17. 30-Day vs 90-Day Prescription Supply Study (1-Year Adherence)

18. ARTEMIS Voucher Use

19. TREAT Study

20. TREAT Study Principal Findings (30 Days)

21. TREAT Study Clinical Implications

22. SWAP-4 Study Design

23. SWAP-4 Study Results and Conclusions

24. Conclusion

25. Website References

26. Abbreviations

27. Abbreviations (cont)